MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$19,805,559
Income tax benefit
(provision)
-$851,659
Pre-tax net loss
-$20,657,218
Change in fair value of
equity payable
-$226,262
Interest expense
-$131,350
Loss from operations
-$20,752,130
Total operating
expenses
$20,752,130
Impairment of in-process
research and development
$18,647,903
General and
administrative
$1,739,174
Research and development
$365,053
Back
Back
Income Statement
source: myfinsight.com
zvsa: the income statement
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)